Pulmonary infiltrates after heart-lung transplantation: evaluation by serial transbronchial biopsies.
Since January 1988, prospective serial transbronchial lung biopsies have been performed as a diagnostic procedure to facilitate the care of recipients of heart-lung transplants. Eighty-five cardiac and 70 transbronchial lung biopsies have been prospectively performed in 10 patients beginning within the first week of transplantation. Forty-eight percent (34/70) of the transbronchial lung biopsies and 16.5% (14/85) of the heart biopsies were positive for either rejection or infection. Pulmonary rejection was evident by a perivascular lymphocytic infiltrate that cleared with pulse steroid therapy. Pulmonary and cardiac rejection were present synchronously on six occasions and asynchronously on 16 occasions (nine pulmonary and seven cardiac). Four patients had early cytomegalovirus pneumonitis on biopsy specimen and were successfully treated with ganciclovir. Of the 40 clinically indicated biopsies, 29 (72.5%) were positive for rejection or infection and guided subsequent therapy. In summary, transbronchial lung biopsies have provided prompt (within 24 hours) serial diagnostic information that has guided successful treatment of infection (cytomegalovirus, aspergillosis, and Pneumocystis) and rejection. Asynchronous rejection of the heart and lungs has been conclusively demonstrated. With the early detection of rejection and infection, we are optimistic that chronic airway disease in patients with a heart-lung transplant may be reduced.
Starnes
V A
VA
Department of Cardiovascular Surgery, Stanford University School of Medicine, Calif.
Theodore
J
J
Oyer
P E
PE
Stinson
E B
EB
Moreno-Cabral
C E
CE
Sibley
R
R
Barry
G
G
Shumway
N E
NE
D000293:Adolescent; D000328:Adult; D001706:Biopsy / Q000379:methods; D001980:Bronchi / Q000473:pathology*; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000209:etiology; D005260:Female; D015774:Ganciclovir / Q000627:therapeutic use; D006084:Graft Rejection; D006085:Graft Survival; D016041:Heart-Lung Transplantation / Q000009:adverse effects*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D008297:Male; D009206:Myocardium / Q000473:pathology*; D009926:Organ Preservation; D011024:Pneumonia, Viral / Q000188:drug therapy / Q000209:etiology; D011183:Postoperative Complications / Q000473:pathology*; D011446:Prospective Studies; D011788:Quality of Life; D013997:Time Factors
D015774:Ganciclovir